Android app on Google Play

OXiGENE (OXGN) Reports Publication of Encouraging Data from ZYBRESTAT Phase 1 w/ Avastin

June 6, 2012 4:12 PM EDT Send to a Friend
Get Alerts OXGN Hot Sheet
Trade OXGN Now!
Join SI Premium – FREE
OXiGENE, Inc. (Nasdaq: OXGN), announced the publication of key clinical data from a Phase 1 trial combining fosbretabulin (ZYBRESTAT, combretastatin A4 phosphate, or CA4P), its lead vascular disrupting agent (VDA), with the anti-VEGF antibody bevacizumab (Avastin) to treat patients with advanced solid tumors, without the use of any cytotoxic chemotherapy, and receiving only the combined two anti-vascular drugs.

A total of 15 patients with a median age of 51 years were enrolled in this Phase 1 trial. Nine of 14 patients (60%) treated experienced disease stabilization, and one patient with ovarian cancer had a CA125 response that lasted for more than one year. The combination of CA4P and bevacizumab appeared to be well tolerated. This trial was the first to combine a vascular disrupting agent with an anti-angiogenic monoclonal antibody. Results indicated that CA4P induced profound tumor vascular changes alone which were maintained by the addition of bevacizumab, thus demonstrating the complementary therapeutic effect of combination vascular disrupting and anti-angiogenic agents.

The data from the Phase 1 trial were published in the current issue of Clinical Cancer Research in an article titled, "Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer," by Paul Nathan, MBBS, PhD, FRCP, Consultant Medical Oncologist and Director of R&D Mount Vernon Cancer Centre, Northwood, United Kingdom, and principal investigator for the trial.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment